GetMedford Inc.

Cover Block

PUBLIC

Name	GetMedford Inc.
Tagline	Online pharma marketplace for authentic meds in Nigeria (B2C/B2B)
Headquarters	Yola, Nigeria
Founded	2023
Stage	Seed
Business Model	Marketplace
Industry	Healthtech
Technology	Software (Non-AI)
Geography	Sub-Saharan Africa
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://getmedford.com/
• Google Play: https://play.google.com/store/apps/details?id=com.getmedford.getmedford

Executive Summary

PUBLIC

GetMedford is building a dual-sided pharmaceutical marketplace in Nigeria, a bet that directly addresses the twin crises of counterfeit drugs and supply chain fragmentation in one of Africa's largest economies [Punch Nigeria]. Founded in 2023 by pharmacist Adamu Muhammad, the company connects patients to authentic, affordable medicines via home delivery while also serving hospitals and pharmacies with a B2B bulk procurement platform [Punch Nigeria]. The founding wedge is a supply-side guarantee of authenticity, with the company reporting partnerships exclusively with manufacturers approved by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) [Punch Nigeria].

Founder Adamu Muhammad brings over 15 years of healthcare logistics experience from roles at Healthbridge Africa and Helium Health, while co-founder Habibou Moussa provides technical depth as the backend and API specialist [TechParley, Habibou Moussa LinkedIn]. The venture is backed by the pan-African accelerator MEST, though the specific terms and size of any seed funding remain undisclosed [F6S]. Early traction, as reported in regional press, includes over 1,200 individual customers and partnerships with more than 100 institutional buyers [Punch Nigeria].

Over the next 12-18 months, the key monitorables are the execution of a stated roadmap to expand into more Nigerian states and the integration of AI-driven demand forecasting, moves that would test both operational scalability and technological differentiation beyond a basic marketplace model.

Data Accuracy: YELLOW -- Key operational metrics and founder background are sourced from a single regional news outlet and founder profiles; independent corroboration is limited.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Marketplace
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Sub-Saharan Africa
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Undisclosed

Company Overview

PUBLIC

GetMedford Inc. was founded in 2023 to address a specific, acute problem in Northern Nigeria: the proliferation of counterfeit and unaffordable medicines [Punch Nigeria]. The company, headquartered in Yola, Nigeria, operates as an online pharmaceutical marketplace, connecting patients and healthcare institutions with verified suppliers [LinkedIn]. Its founding story centers on a pharmacist-entrepreneur, Adamu Muhammad, leveraging over 15 years of experience in healthcare logistics to build a tech-driven solution for supply chain integrity [TechParley].

Key operational milestones are anchored in its initial market penetration. Within its first year, the company established a dual-sided marketplace, launching both a B2C platform for patient home delivery and a B2B platform for bulk procurement by hospitals and pharmacies [Punch Nigeria]. It secured backing from the pan-African accelerator MEST, which provided early-stage support [F6S]. By the time of its first major press profile, GetMedford reported serving over 1,200 individual customers and partnering with more than 100 hospitals and pharmacies [Punch Nigeria].

The company's stated mission is to ensure access to safe, affordable, and reliable medicines for every Nigerian, a goal it pursues through exclusive partnerships with NAFDAC-approved manufacturers [Punch Nigeria]. Its roadmap, as quoted by leadership, includes geographic expansion into more states and plans to integrate AI-driven demand forecasting to optimize inventory [Punch Nigeria].

Data Accuracy: YELLOW -- Company details and milestones are sourced from a single regional press article and accelerator profiles; financials and legal entity are not publicly verified.

Product and Technology

MIXED

The core product is a dual-sided marketplace that addresses two distinct but related access problems in Nigeria's pharmaceutical sector. For consumers, GetMedford operates a B2C platform where patients can order authenticated medicines for home delivery, a direct response to the prevalence of counterfeit drugs [Punch Nigeria]. For institutional buyers, the company provides a B2B platform enabling hospitals and pharmacies to purchase inventory in bulk directly from licensed manufacturers, aiming to improve affordability and supply chain reliability [Punch Nigeria].

The company's primary technical differentiation is not a novel software layer but a rigorous sourcing and verification protocol. It claims to partner exclusively with manufacturers and distributors approved by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) [Punch Nigeria]. This gatekeeping function is central to its value proposition of guaranteeing authenticity. The public-facing technology includes a consumer-facing mobile application available on Google Play [Google Play] and, by inference, a web-based procurement portal for business clients. The technical stack is not detailed in public materials, though the co-founder and CTO's background points to a backend built on Java and Python with a focus on API design and integration [Habibou Moussa LinkedIn].

Public traction metrics, while self-reported, provide a scale for the platform's current operations. The company states it has served over 1,200 individual customers and partnered with more than 100 hospitals and pharmacies [Punch Nigeria]. These figures suggest a marketplace that has achieved initial liquidity, though the split between B2C and B2B transaction volume is not disclosed. The logistics network enabling delivery is described as "growing" but specifics on last-mile capabilities or partnerships are not available [Punch Nigeria].

Data Accuracy: YELLOW -- Product claims are consistent across the company's website and a single press article. Traction metrics are company-sourced and not independently verified. Technical stack details are inferred from founder profiles.

Market Research

PUBLIC The Nigerian pharmaceutical market is defined by a fundamental tension between a massive, growing demand for medicine and a fragmented, unreliable supply chain that leaves millions vulnerable to counterfeit drugs and stockouts. This gap, which GetMedford aims to address, is not a niche problem but a systemic public health challenge with clear economic drivers.

Third-party market sizing for Nigeria's pharmaceutical sector is not cited in the company's available coverage. However, analogous regional reports provide context. A 2023 report by the research firm Briter Bridges estimated the total value of Africa's pharmaceutical market at $45 billion, with Nigeria accounting for a significant portion [Briter Bridges, 2023]. The World Health Organization has repeatedly highlighted that sub-Saharan Africa bears the highest burden of substandard and falsified medical products, with Nigeria frequently cited as a major market for such goods [WHO]. These reports frame the scale of the problem GetMedford is tackling, though the company's specific serviceable obtainable market (SOM) within Nigeria's northern states remains unquantified in public materials.

Demand is propelled by several structural tailwinds. Nigeria's population, estimated at over 220 million, is both large and young, driving consistent baseline demand for pharmaceuticals. Urbanization is increasing, but access to reliable pharmacies remains concentrated in major cities, creating a delivery opportunity for underserved peri-urban and rural populations. Furthermore, the rise of chronic non-communicable diseases like hypertension and diabetes necessitates regular, long-term medication, shifting purchase patterns toward recurring needs rather than acute episodes. The company's cited partnership with over 100 hospitals and pharmacies suggests it is initially targeting institutional bulk buyers, a segment with more predictable procurement cycles than individual consumers [Punch Nigeria].

Key adjacent markets include general e-commerce logistics and telemedicine. Companies like Jumia have demonstrated the viability of last-mile delivery for consumer goods in Nigeria, though the regulatory and cold-chain requirements for pharmaceuticals are more stringent. Telemedicine platforms such as Helium Health's MDaaS provide diagnostic and consultation services, creating potential upstream referral partnerships for medication fulfillment. The regulatory environment, centered on the National Agency for Food and Drug Administration and Control (NAFDAC), is a critical macro force. GetMedford's claim to partner exclusively with NAFDAC-approved manufacturers is a direct response to this, positioning authenticity and regulatory compliance as its primary wedge against informal and gray-market sellers [Punch Nigeria].

Africa Pharma Market (2023 est.) | 45 | $B

The available data points to a large addressable region, but the precision needed to model GetMedford's immediate opportunity is absent. The company's traction metrics of 1,200 individual customers and 100+ institutional partners [Punch Nigeria] offer a baseline for early adoption within a specific geographic and operational wedge, rather than a claim on the broader market.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous regional reports, not company-specific analysis. Traction claims are sourced from a single regional news outlet.

Competitive Landscape

MIXED GetMedford enters a Nigerian pharmaceutical supply chain defined by fragmentation and inefficiency, positioning itself as a digital connector between regulated suppliers and underserved buyers, both retail and wholesale.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
GetMedford	B2C/B2B online marketplace for authentic medicines in Nigeria, focusing on Northern regions.	Seed; Accelerated by MEST.	Dual B2C/B2B model from launch; stated focus on NAFDAC-approved supply chain integrity.	[Punch Nigeria]
DrugStoc	B2B pharmaceutical marketplace connecting manufacturers to healthcare providers across Nigeria.	Venture-backed; raised $4.4M Series A in 2022.	Focused exclusively on the B2B institutional segment with a tech-enabled distribution platform.	[Crunchbase]
Lifestores Pharmacy	Omnichannel pharmacy platform operating retail stores and an online marketplace in Nigeria.	Venture-backed; raised $3M pre-Series A in 2022.	Integrated offline retail footprint with online presence, offering both fulfillment and patient services.	[Crunchbase]

The competitive map splits along customer segment and asset strategy. In the B2B wholesale segment, DrugStoc is the incumbent challenger, having secured institutional funding to scale its model of digitizing procurement for hospitals and pharmacies [Crunchbase]. Its focus is purely on the professional buyer, a strategy that may allow deeper feature development and sales force specialization. Lifestores Pharmacy represents an integrated omnichannel model, combining physical retail pharmacies with an online marketplace [Crunchbase]. This approach competes directly with GetMedford's B2C proposition while also serving B2B needs through its store network, creating a hybrid defensive moat based on last-mile physical presence.

GetMedford's stated edge today rests on its simultaneous pursuit of both B2C and B2B customers from a single platform, and its public emphasis on partnering exclusively with NAFDAC-approved manufacturers to combat counterfeits in Northern Nigeria [Punch Nigeria]. This dual-market wedge could allow it to aggregate demand more efficiently in its initial regional focus. However, this edge is perishable. It depends on execution in logistics and trust-building in a region where counterfeit penetration is high. A more funded B2B pure-play like DrugStoc could decide to launch a B2C arm, or a well-capitalized omnichannel player like Lifestores could deepen its wholesale operations, either move eroding GetMedford's differentiation.

The company is most exposed in two areas. First, it lacks the institutional funding and scale of its named competitors, which limits its ability to invest in logistics infrastructure, sales teams, or inventory that could lock in partners. Second, its model does not currently own physical last-mile assets or a proprietary logistics network, making it reliant on third-party delivery partners. This creates vulnerability against competitors who control fulfillment, either through owned stores like Lifestores or through scaled B2B warehousing and distribution.

The most plausible 18-month scenario is one of regional consolidation and segment specialization. If GetMedford can demonstrate superior unit economics and supplier loyalty in its Northern Nigeria focus region, it becomes an attractive acquisition target for a national player seeking regional density or a B2C capability. The loser in this scenario would be a generic, undifferentiated online pharmacy aggregator without a clear geographic or supply chain wedge. A winner, however, could emerge if GetMedford's integrated B2B/B2C data proves uniquely valuable for demand forecasting, allowing it to secure a strategic partnership or dedicated funding to build out a logistics layer that others lack.

Data Accuracy: YELLOW -- Competitor profiles and funding stages are confirmed via Crunchbase. GetMedford's positioning is sourced from a single regional press article [Punch Nigeria]; its competitive differentiation claims are not independently verified.

Opportunity

PUBLIC

If GetMedford can reliably connect Nigeria's fragmented pharmaceutical supply chain, the prize is a dominant marketplace serving a population of over 200 million people with a critical, non-discretionary need.

The headline opportunity is to become the default digital procurement and distribution layer for Nigeria's pharmaceutical industry. The company is not just another e-commerce site; it is positioning itself as essential infrastructure that addresses a public health crisis of counterfeit and inaccessible medicines [Punch Nigeria]. This outcome is reachable because the company has already established the foundational wedge: a dual-sided marketplace that aggregates demand from both end consumers and institutional buyers, while restricting supply to verified, NAFDAC-approved sources. The early traction, cited as over 1,200 individual customers and partnerships with more than 100 hospitals and pharmacies, demonstrates initial proof of a fragmented market willing to transact on a centralized platform [Punch Nigeria]. For a country where an estimated 17% of drugs are substandard or falsified, a trusted, tech-enabled aggregator could command significant pricing power and market share by reducing search costs and guaranteeing authenticity.

Growth from this wedge could follow several concrete paths. The most plausible scenarios hinge on leveraging the initial B2B pharmacy network to capture a larger share of institutional spending before expanding geographically or into adjacent services.

Scenario	What happens	Catalyst	Why it's plausible
B2B Anchor Expansion	GetMedford becomes the primary bulk procurement partner for its existing network of 100+ hospitals and pharmacies, moving from a discovery platform to a managed inventory service.	Securing a strategic partnership or dedicated supply agreement with a major pharmaceutical manufacturer or distributor.	The company's stated model is built on direct manufacturer relationships [Punch Nigeria]. Deepening these ties to offer exclusive stock or better terms would lock in institutional customers seeking reliability.
Geographic Dominance in the North	The company achieves market leadership in Northern Nigeria, its stated initial focus, by saturating urban and peri-urban areas before competitors establish a foothold.	Successful rollout of the "growing logistics network" mentioned in coverage to overcome last-mile delivery challenges in the region [Punch Nigeria].	The founder's 15+ years in healthcare logistics, as reported, provides domain expertise critical for navigating complex regional supply chains [TechParley]. A concentrated win in one region is a more capital-efficient path to scale.
AI-Driven Supply Orchestration	GetMedford evolves from a marketplace to a predictive supply chain platform, using transaction data to forecast demand and optimize inventory for its partners, reducing stockouts and waste.	The integration of the AI-driven demand forecasting tools mentioned in the company's stated roadmap [Punch Nigeria].	The accumulation of transactional data from B2B and B2C activity creates a proprietary dataset on regional drug consumption patterns, a potential data moat competitors cannot easily replicate.

Compounding for GetMedford would manifest as a classic two-sided network effect reinforced by a trust-based brand. Each new pharmacy or hospital onboarded increases the platform's aggregate buying power, which can be leveraged to secure better terms from manufacturers. Better terms and a wider product selection, in turn, attract more institutional buyers and individual consumers. Simultaneously, every verified transaction builds the platform's reputation as a source of authentic medicine, which is a powerful deterrent against customer churn in a market plagued by counterfeit goods. The early signal of this flywheel is the company's reported growth in partner institutions, suggesting the value proposition is resonating with the supply side of the network [Punch Nigeria].

The size of the win, should the B2B anchor expansion scenario play out, can be framed by a comparable. DrugStoc, a Nigerian B2B pharmaceutical marketplace, raised a $4.4 million Series A round in 2022 [Crunchbase]. While direct valuation figures are not public, this level of institutional investment signals investor belief in the scalability of the model. If GetMedford can capture a similar or greater share of the institutional pharmaceutical procurement market,a market worth billions annually,achieving a valuation in the high tens or low hundreds of millions of dollars is a plausible outcome (scenario, not a forecast). The ultimate prize is a company that controls a critical segment of a nation's healthcare infrastructure.

Data Accuracy: YELLOW -- Traction and partnership metrics are sourced from a single regional news outlet. Founder background and product claims have partial corroboration across multiple sources.

Sources

PUBLIC

1. [Punch Nigeria] GetMedford deploys tech to boost genuine medicines access | https://punchng.com/getmedford-deploys-tech-to-boost-genuine-medicines-access/

2. [TechParley] Adamu Muhammad’s GetMedford Tackles Nigeria’s Counterfeit Medicine Crisis with Tech | https://techparley.com/adamu-muhammads-getmedford-tackles-nigerias-counterfeit-medicine-crisis-with-tech/

3. [F6S] Adamu Muhammad profile | https://www.f6s.com/adamu-muhammad

4. [LinkedIn] Habibou Moussa - Co-founder & CTO at GetMedford Inc | Backend Developer | API Design & Integration Specialist | https://www.linkedin.com/in/habibou-moussa/

5. [Google Play] Getmedford - Apps on Google Play | https://play.google.com/store/apps/details?id=com.getmedford.getmedford

6. [Crunchbase] DrugStoc Company Profile & Funding | https://www.crunchbase.com/organization/drugstoc

7. [Crunchbase] Lifestores Pharmacy Company Profile & Funding | https://www.crunchbase.com/organization/lifestores-pharmacy

8. [Briter Bridges, 2023] Africa's Pharmaceutical Market Report | https://briterbridges.com/reports